Experiences with

Lymphocytic leukemia

Limited-duration combination therapies are starting to reshape how chronic lymphocytic leukemia (CLL) will be treated, but which combination is best is still unclear. https://cllsociety.org/2024/12/acalabrutinib-and-obinutuzumab-for-frontline-cll-treatment/

Check it out - https://www.patientpower.info/video/chronic-lymphocytic-leukemia/early-cll-treatment-options-what-to-know?

Abstract report in New England Journal of Medicine Published February 5, 2025 No real new information here and I'm surprised anyone was recruited for this study as the control arm is chemoimmunotherapy and no account appears to have been taken for unmated IGHV or 17p/TP53 as the patients were

https://healthtree.org/cll/community/events/feb2025-chronic-lymphocytic-leukemia-immune-system

https://www.patientpower.info/chronic-lymphocytic-leukemia/reframing-cll-a-clinical-trial-journey-down-under

The association of MRD status as a surrogate end point of clinical outcome in chronic lymphocytic leukemia (CLL) has not been established in the era of targeted agents.

[/i] * * * [u]Year in Review: Chronic Leukemia — Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more[/u], by Ian Ingram, Managing Editor, MedPage Today December 10, 2024, Last Updated December 11, 2024 Developments in chronic lymphocytic

Richter transformation involves the evolution of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma, Tedeschi and colleagues noted in their introduction.

Hi all, I was intrigued by this article: Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380985/ Has anyone explored this?

Below are the notes: There is mild leukocytosis with lymphocytosis The lymphocytes comprise of predominantly small mature forms and a subpopulation with clumped chromatin highly suspicious for chronic lymphocytic leukemia. I know this isn't a dr site but is it time to visit him again?

[i][/i] [i]"Oral therapies targeting receptors in a blood cancer called chronic lymphocytic leukemia (CLL) have transformed outcomes with for those with this disease.

Two studies presented exciting advancements in the treatment of chronic lymphocytic leukemia (CLL): Jennifer Brown, MD, PhD, presented findings that a novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax

We've had a few other posts recently regarding the TME; [i] • [/i]Targeting the tumor microenvironment for treating double refractory chronic leukemia posted by newyork917 https://healthunlocked.com/cllsupport/posts/private/150923620/targeting-the-tumor-microenvironment-for-treating-double-refractory-chronic-lymphocytic-leukemia

[i] Abstract[/i] [i][/i] [i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis.

Ohio State Univeristy, FYI- REMISSION- 8 PLUS YEARS OUT https://www.patientpower.info/chronic-lymphocytic-leukemia/the-lowest-levels-of-cll-ive-ever-seen?

The first one was done in June 2022): HEMATOPATHOLOGY CONSULTATION Date Ordered: 11/7/2024 INTERPRETATION FINAL DIAGNOSIS: PERIPHERAL BLOOD: - CHRONIC LYMPHOCYTIC LEUKEMIA IMMUNOLOGIC CHARACTERIZATION BY FLOW CYTOMETRY, PERIPHERAL BLOOD: - KAPPA (WEAK) MONOTYPIC B LYMPHOID CELL POPULATION

leukemia/small lymphocytic lymphoma (A-CLL/SLL) is a histologically aggressive subtype of CLL/SLL that lies in between conventional CLL/SLL (C-CLL/SLL) and Richter transformation (RT) on the biological spectrum.

I was diagnosed in February with CCL Chronic lymphocytic leukemia. It was discovered because of kidney problems. I’m having treatment for that and everything is going well according to my hematologist. I made the tests in February regarding bence jones, lambda and everything returned negative.

Acalabrutinib plus obinutuzumab without venetoclax is also a fixed-duration therapy for the treatment of chronic lymphocytic leukemia (CLL).

leukemia?